In today’s one-on-one interview, we talk with Dimitrios A. Pappas, M.D., MPH, scientific director of the Corrona RA Registry and an adjunct professor with Columbia University. He and his team recently published results from the registry in ACR Open Rheumatology which show that rheumatoid arthritis patients may be able to maintain remission or low disease activity with etanercept (Enbrel, Amgen) monotherapy long-term treatment.
Dr. Bradley Marder, medical director of nephrology with Horizon Therapeutics, addresses the role of diet in managing gout.
Gout is not only an intermittent disease that affects peripheral joints, it’s a disease that's systemic in nature and progressive, says Dr. Bradley Marder, medical director of nephrology with Horizon Therapeutics. As a nephrologist, he sees gout as a kidney disease. In this interview, he explains why.
The use of biologics, JAK inhibitors and small molecule medications has become increasingly common for patients with psoriatic arthritis. Findings from the recent Psoriatic Arthritis In America 2020 survey by Health Union shows that of 1,120 patients surveyed, most patients (61 percent) are satisfied with the care they receive from their doctors, but they still struggle with flares and only 12 percent are satisfied with their care plan. In this interview, Brian Green, vice president of community development at Health Union, reviews the results of their latest survey.
Today, we talk with Dr. Sarah French, a rheumatologist with the University of California at San Francisco. Dr. French recently published a review in Current Osteoporosis Reports that addresses successes and failures in quality improvement initiatives in osteoporosis. Through the MIPS program, healthcare providers are required to select six quality measures. And while they may be performing well on osteoporosis screenings, their track record on osteoporosis management isn't fairing as well. Dr. French has identified this as an area for improvement. In this interview, she explains how.
In today’s one-on-one interview, we talk with Dr. Richard Furie who is chief of rheumatology at Northwell Health in New York. Dr. Furie is the lead investigator of a study on lupus nephritis just published in the New England Journal of Medicine. Dr. Furie and colleagues from the Feinstein Institutes for Medical Research reported that belimumab with standard therapy has been shown to be an effective treatment for lupus nephritis. If the treatment is approved by the U.S. Food and Drug Administration, it would be the first of its kind for this condition. In this presentation, Dr. Furie tell us more.
Three key issues with using the technology over in-person visits.
Care of rheumatic patients must factor in cradiovascular risk and conditions.
The recently published American College of Rheumatology guidelines on reproductive health is a great resource for rheumatologists.
How rheumatologists use telemedicine during COVID-19.
Leveraging telemedicine during COVID-19.
An expert discusses the role of the rheumatologist in managing cardiovascular risk factors as well as current gaps in the field.
An expert explains resources for pain related to rheumatic conditions.
MIS-C is a condition recently recognized in children with COVID-19.
Rheumatologists and OB-GYNs must communicate openly with each other and to patients with rheumatic diseases who are considering pregnancy.
How providers of multiple specialists can come together to help 1 patient.
An expert dermatologist explains.
COVID-19 is associated with its own cytokine storm syndrome.
When a rheum patient might need to consult with a dermatologist.
How the 2 specialties play a role in each other.
An expert discusses the risks that rheumatic diseases pose for pregnancies as well as the conversations rheumatologists need to have with their patients.
Alternate therapies can be more effective than opioids.
Facets of managing pain for rheumatology patients.
Managing CTDs may have an overall benefit on cardiovascular health.
Osteoporosis
Hip fractures in the United States and developed countries have been declining for over four decades. But why? Dr. Timothy Bhattacharyya, an orthopedic surgeon and head of Orthopedics Research for the Clinical Trials and Outcomes Branch of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, delved into the root cause of this phenomenon in a study published in July in JAMA Internal Medicine.
Rheumatology
In this week's one-on-one interview, we talk with Dr. Jeffrey Curtis of the University of Alabama. We spoke about the use of activity trackers as a tool to record and track arthritic flare-ups. The device has been found to be useful in improving patient care or as Dr. Curtis says, “we need to right-size care” by giving patients the right care at the right time.” In this interview, he explains how an activity tracker can make such a huge difference in the care patients receive.
The ICD-10 code for nr-ax-SpA should be programmed into EHRs in October.
There are not typical diagnostic criteria used to diagnose nr-ax-SpA.
Rheumatology
In this week's news roundup from Rheumatology Network, we highlight a one-on-one discussion with Dr. Fotios Koumpouras, fellowship program director for rheumatology at Yale School of Medicine. Rheumatology education has undergone some changes since the start of the pandemic, he says. In this interview, he tells us how.
Patients and clinicians alike will have a better understanding of clinical processes.
